share_log

Raymond James Maintains Outperform on Leap Therapeutics, Raises Price Target to $18.5

Benzinga ·  Jul 13, 2023 04:38

Raymond James analyst Steven Seedhouse maintains Leap Therapeutics (NASDAQ:LPTX) with a Outperform and raises the price target from $17 to $18.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment